GPNMB-targeting Chimeric Antigen Receptor T-Cell Therapy (GCAR1) for a patient with metastatic epithelioid hemangioendothelioma (EHE) (CLIC-YYC-GPNMB-02)
Summary
Scientists in Calgary have joined forces to develop a new type of medicine for patients with rare cancers. This cutting edge treatment will now be tested in a single patient here with an incurable disease who has no more treatment options.
Eligibility
Eligible ages: 0 to 100
Inclusion criteria:
This study is only for a pre-identified single patient.
Exclusion criteria:
This study is only for a pre-identified single patient.
Participate
Additional information
Contact information
n/a
Principal investigator:
Victor Anthony Lewis
Clinical trial:
Yes
REB-ID:
HREBA.CC-23-0010